A randomised phase II study evaluating cediranib versus cediranib and saracatanib in patients with relapsed metastatic clear cell renal cancer.

Trial Profile

A randomised phase II study evaluating cediranib versus cediranib and saracatanib in patients with relapsed metastatic clear cell renal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cediranib (Primary) ; Saracatinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms COSAK
  • Most Recent Events

    • 06 Jun 2017 Results of retrospective analysis assessing dynamic changes in prognostic marker to predict survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Jan 2016 Results published in the Annals of Oncology
    • 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top